Wedge Capital Management L L P NC Has $33.34 Million Position in DaVita Inc. $DVA

Wedge Capital Management L L P NC trimmed its holdings in DaVita Inc. (NYSE:DVA) by 6.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 250,918 shares of the company’s stock after selling 17,526 shares during the quarter. Wedge Capital Management L L P NC owned about 0.35% of DaVita worth $33,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the business. Northern Trust Corp lifted its stake in DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after buying an additional 149,858 shares during the period. Gates Capital Management Inc. increased its stake in shares of DaVita by 0.7% in the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock valued at $110,476,000 after acquiring an additional 4,698 shares in the last quarter. Amundi lifted its position in shares of DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after acquiring an additional 71,304 shares during the period. Epoch Investment Partners Inc. boosted its stake in DaVita by 10.7% during the first quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock worth $62,400,000 after acquiring an additional 39,485 shares in the last quarter. Finally, KBC Group NV grew its holdings in DaVita by 38.7% in the second quarter. KBC Group NV now owns 374,749 shares of the company’s stock worth $53,383,000 after purchasing an additional 104,554 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Down 0.8%

Shares of DaVita stock opened at $115.18 on Friday. DaVita Inc. has a 52 week low of $113.97 and a 52 week high of $179.60. The business has a 50 day moving average price of $121.38 and a 200-day moving average price of $131.45. The company has a market cap of $8.13 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 0.87 and a beta of 1.00.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.17 by ($0.66). The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on DVA shares. Cowen reiterated a “hold” rating on shares of DaVita in a report on Monday, November 3rd. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. UBS Group reissued a “buy” rating on shares of DaVita in a research note on Monday, December 15th. Bank of America decreased their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday, September 10th. Finally, TD Cowen cut their target price on DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a report on Monday, November 3rd. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $148.00.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.